Zoghbi and Bird Awarded Horwitz Prize for Rett Syndrome Breakthroughs

Before the work of these two scientists, Rett syndrome was widely viewed as a permanent and untreatable condition. In 1999, Zoghbi established a critical link between the disorder and the MeCP2 protein, demonstrating that neurological function relies on the precise maintenance of MeCP2 levels. Her research revealed that both insufficient and excessive amounts of this protein trigger distinct neurological deficits, ranging from autism to juvenile-onset schizophrenia.

Bird provided the necessary chemical context for these findings during his work in the 1980s and 1990s. He identified CpG islands—specialized DNA clusters—and characterized MeCP2 as a molecular switch that silences genes by recognizing methyl groups. This discovery fundamentally changed the medical understanding of how genes are turned on or off without altering the underlying genetic code.

Perhaps most significant is the pair’s contribution to the concept of reversibility. By creating mouse models, Bird’s group demonstrated in 2007 that reactivating MeCP2 could alleviate neurological symptoms. Zoghbi’s team further validated this potential for clinical intervention through oligonucleotide therapy. These insights now anchor a new wave of gene replacement and RNA-regulating drug trials, including TSHA-102 and ION 440. The Horwitz Prize committee highlighted this transition from basic discovery to therapeutic development as a hallmark of their research, noting that the award has historically served as a strong indicator of future Nobel recognition.